Next Generation Sequencing Market Report 2018: Acute Analysis of Global Demand and Supply 2026 With Top Players Thermo Fisher Scientific Inc., Agilent Technologies Inc., BioMerieux S.A., F. Hoffmann-La Roche Ltd, Qiagen N.V.

Major factors driving growth of the next generation sequencing market are early detection of cancer and infectious diseases and increasing partnership among academic and industry partnerships for research and development. For academic institutions, these collaborations help in commercialization of their discoveries from basic research to medical products. For instance, in March, 2018, Cofactor Genomics, a U.S.-based developer of Cofactor Paragon (RNA analysis tool) signed agreement with National Cancer Institute, and other three other pharma and academic institutes to show clinical ability of its product.

Download PDF Brochure of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-pdf/158

Market Dynamics

Increasing prevalence of cancer and infectious diseases and ability of NGS platforms to detect cancers and infectious diseases are expected to drive growth of the next generation sequencing market during the forecast period. The use of NSG for study of cancer cells mutations is increasing and the implementation of this technology has considerably aided in early diagnosis of diseases. In the U.S., over 1.69 million new cancer cases were detected in 2016; whereas the global incidence of cancer was around 14 million new cases in 2012 and an annual 19.3 million cases are estimated by 2025. However, interpretation of complex data, lack of skilled professionals, and issues related to security of NGS data are expected to limit growth of the market.

Rising Demand For Early Detection Of Cancer And Infectious Diseases To Drive Growth Of The NGS Market

The chances of successful treatment increase when cancer and infectious diseases are detected at the early stage. One of the major factors that drive growth of the next generation sequencing market is the rising prevalence of cancer and other infectious diseases. According to the World Health Organization (WHO), in 2012, new cases of cancer was around 14 million and the incidence is estimated to increase to 70% by 2030.

As per statistics published by National Cancer Institute (NCI), in 2016, 1,685,210 new cases of cancer were diagnosed in the U.S. alone. In 2015, WHO reported 8.8 million deaths occurred due to cancer. According to American Cancer Society (ACS), in 2017, around 161,360 cases of prostate cancer were reported in the U.S alone. ACS, in 2015, also reported 4.5 million new cancer cases in China and the number is expected to increase to 7.6 Mn by 2020. Morbidity cases in tuberculosis, salmonella, and meningococcal disease was as high as 90,000 in the U.S. in 2016. Therefore, increasing demand for early diagnosis of cancer and infectious diseases, to aid in better outcome, is in turn expected to aid in growth of the market over the forecast period.

Competitive Analysis

Key players in the next generation sequencing market include Thermo Fisher Scientific Inc., Agilent Technologies, Inc., BioMerieux S.A., F. Hoffmann-La Roche Ltd, Qiagen N.V., Illumina, Inc., Oxford Nanopore Technologies, and Beijing Genomics Co. Ltd.

Request For Customization Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-customization/158

Detailed Segmentation:

Global Next Generation Sequencing Market, By Technology:
Whole Genome Sequencing
Whole Exome Sequencing
RNA Sequencing
Targeted Re-sequencing
Others

Global Next Generation Sequencing Market, By Application:
Drug Discovery
Personalized Medicine and Genetic Screening
Disease Diagnosis
Agriculture and Animal Research
Others

Global Next Generation Sequencing Market, By End User:
Hospital
Research Centers
Pharma and Biotech Firms
Others

Increasing demand for DNA testing

Demand for DNA testing is increasing, due to advancements in whole genome and exome sequencing procedures, faster results and cost effectives of the process as compared to genotyping based DNA microarray. In December, 2014, the first commercial sequencer, MinIon, using Nanopore technology was introduced by Oxford Nanopore Technologies. The sequencer identifies DNA by measuring the changes in the electrical conductivity generated DNA strands passed through biological pore. This technology enabled the detection of outbreaks such as Zika virus. Furthermore, GenapSys, a U.S.-based developer of DNA sequencing technologies for applied genomic testing, introduced GENIUS sequencer, which can sequence DNA anywhere.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.